Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Can a GDP-liganded G-protein be active?

Thomas Wieland1, Martin C Michel

  • 1Department of Pharmacology and Toxicology, University of Heidelberg, Mannheim, Germany.

Molecular Pharmacology
|June 28, 2005
PubMed
Summary

G-protein activation typically requires GTP, but new research suggests GDP-liganded Gs can activate adenylyl cyclase. This challenges the established model of G-protein signaling and effector activation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Botulinum Toxin Type A Injections in the Bladder Wall-An Effective Treatment for Urinary Incontinence with Low Long-Term Adherence.

Toxins·2026
Same author

Letter regarding Pini, A., Nardini, P., Zizi, V., Molino, M., Calvani, M., Carrozzo, F., … Filippi, L. (2026). β3-adrenoceptor agonism exerts lung protection in a rat model of bronchopulmonary dysplasia. Br J Pharmacol, in press.

British journal of pharmacology·2026
Same author

A year in pharmacology: new drugs approved by the US food and drug administration in 2025.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025
Same author

Correction to: Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.

World journal of urology·2025
Same author

Biased Agonism at β-Adrenoceptor Subtypes: A Drug Development Perspective.

Handbook of experimental pharmacology·2025

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Signaling

Background:

  • G-protein activation is a critical cellular process involving the exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) on the G-protein alpha-subunit.
  • This nucleotide exchange is traditionally viewed as essential for initiating downstream signaling cascades by enabling G-protein interaction with effectors.
  • The heterotrimeric G-protein Gs plays a key role in coupling receptors to the activation of adenylyl cyclase, a crucial enzyme in cyclic AMP production.

Discussion:

  • Recent findings challenge the necessity of GTP binding for effector activation by Gs.
  • Uğur et al. (2005) present data indicating that GDP-bound Gs can activate adenylyl cyclase with comparable potency and efficacy to GTP-bound Gs.
  • This observation necessitates a re-evaluation of the canonical model of G-protein mediated signaling.

Key Insights:

  • The canonical model of G-protein activation, requiring GTP for effector interaction, may not universally apply.
  • GDP-liganded Gs demonstrates significant, potent activation of the adenylyl cyclase effector.
  • This finding suggests alternative or parallel pathways for G-protein effector modulation.

Outlook:

  • Further investigation is required to elucidate the precise mechanisms underlying GDP-mediated Gs activation of adenylyl cyclase.
  • Understanding these alternative pathways could reveal new therapeutic targets for diseases involving Gs signaling.
  • Revisiting the role of nucleotide-free or GDP-bound states in other G-protein systems is warranted.

Related Experiment Videos